Unlocking mRNA-driven CRISPR-Cas9 gene therapy via optimizing mRNA and the delivery vectors

Shengyi Wang; Xiaoyu Xu; Tapani Viitala; Yilai Shu; Hongbo Zhang

doi:10.1016/j.omtn.2025.102737

Unlocking mRNA-driven CRISPR-Cas9 gene therapy via optimizing mRNA and the delivery vectors

Shengyi Wang
, Xiaoyu Xu
, Tapani Viitala
, Yilai Shu
, Hongbo Zhang^*

^*Korresponderande författare för detta arbete

Forskningsoutput: Tidskriftsbidrag › Översiktsartikel › Peer review

10 Citeringar (Scopus)

28 Nedladdningar (Pure)

Sammanfattning

RNA forms of CRISPR-Cas9-based gene therapies provide more safer and effective therapeutic outcomes. This paper offers a reference for improving the effects of RNA forms of CRISPR-Cas9-based therapies, through the rational engineering design of mRNA components, combined with novel structural RNAs and novel delivery vehicles.

Originalspråk	Engelska
Artikelnummer	102737
Tidskrift	Molecular Therapy Nucleic Acids
Volym	36
Nummer	4
DOI	https://doi.org/10.1016/j.omtn.2025.102737
Status	Publicerad - dec. 2025
MoE-publikationstyp	A2 Översiktsartikel artikel i en vetenskaplig tidskrift

Åtkomst av dokument

10.1016/j.omtn.2025.102737Licens: CC BY

PIIS2162253125002914Slutlig publicerad version, 7,94 MBLicens: CC BY

https://urn.fi/URN:NBN:fi-fe20251205114798

Åbo Akademi Functional Printing Center
Toivakka, M. (PI), Rosenholm, J. (PI), Anttu, N. (PI), Bobacka, J. (PI), Huynh, T. P. (PI), Peltonen, J. (PI), Wang, X. (PI), Wilen, C.-E. (PI), Xu, C. (PI), Zhang, H. (PI) & Österbacka, R. (PI)
Fakulteten för naturvetenskap och teknik
Utrustning/facilitet: Facilitet

MADNESS: Centre of Excellence in Materials-driven solutions for combatting antimicrobial resistance
Rosenholm, J. (Ansvarig forskare), Porres Paltor, I. (CoPI), Bansal, K. (Koordinator), Lafond, S. (CoPI), Uppstu, P. (CoPI), Viitala, T. (CoPI), Wang, X. (CoPI), Wilen, C.-E. (CoPI), Xu, C. (CoPI), Zhang, H. (CoPI), Lu, Z. (CoI), Verma, J. (CoI), Kumar, V. (CoI), Frejborg, F. (CoI), Wang, S. (CoI), Ran, M. (CoI), Ma, X. (CoI), Yang, W. (CoI), Liang, S. (CoI), Zhang, Y. (CoI), Fan, L. (CoI), Chen, Y. (CoI), Wang, L. (CoI), Zhuang, P. (CoI), Rajan Prakash, D. (CoI), Howaili, F. (CoI), Gulshan, R. (CoI), Yadav, D. (CoI), Pathak, C. (CoI), Mustafa, R. (CoI), DarzianRostami, L. (CoI), Jafari Dargahlou, M. (CoI), Nygård, A. (CoI), Samrat, S. R. (CoI), Rexha, H. (CoI), Shiralizadeh Dezfuli, A. (CoI), Rahman Samrat, S. (CoI), Kohoolat, G. (CoI), Rezaeipour, Y. (CoI), Yadav, D. (CoI), Xia, Q. (CoI), Jafari Dargahlou, M. (CoI), Yang, W. (CoI) & Bayandori, M. (CoI)
Stiftelsen för Åbo Akademi sr
01/01/24 → 31/12/28
Projekt: Stiftelser och fonder
PII: Printed Intelligence Infrastructure
Toivakka, M. (Ansvarig forskare), Xu, C. (CoPI), Bobacka, J. (CoPI), Viitala, T. (CoPI), Rosenholm, J. (CoPI), Österbacka, R. (CoPI), Anttu, N. (CoPI), Huynh, T. P. (CoPI), Peltonen, J. (CoPI), Wang, X. (CoPI), Zhang, H. (CoPI) & Wilen, C.-E. (CoPI)
Finlands Akademi
01/01/24 → 31/12/28
Projekt: Finlands Akademi/Övriga Forskningsråd

Citera det här

@article{b7f98b230cb14fcfade579852307e2a0,

title = "Unlocking mRNA-driven CRISPR-Cas9 gene therapy via optimizing mRNA and the delivery vectors",

abstract = "RNA forms of CRISPR-Cas9-based gene therapies provide more safer and effective therapeutic outcomes. This paper offers a reference for improving the effects of RNA forms of CRISPR-Cas9-based therapies, through the rational engineering design of mRNA components, combined with novel structural RNAs and novel delivery vehicles.",

author = "Shengyi Wang and Xiaoyu Xu and Tapani Viitala and Yilai Shu and Hongbo Zhang",

year = "2025",

month = dec,

doi = "10.1016/j.omtn.2025.102737",

language = "English",

volume = "36",

journal = "Molecular Therapy Nucleic Acids",

issn = "2162-2531",

publisher = "Cell Press",

number = "4",

}

TY - JOUR

T1 - Unlocking mRNA-driven CRISPR-Cas9 gene therapy via optimizing mRNA and the delivery vectors

AU - Wang, Shengyi

AU - Xu, Xiaoyu

AU - Viitala, Tapani

AU - Shu, Yilai

AU - Zhang, Hongbo

PY - 2025/12

Y1 - 2025/12

N2 - RNA forms of CRISPR-Cas9-based gene therapies provide more safer and effective therapeutic outcomes. This paper offers a reference for improving the effects of RNA forms of CRISPR-Cas9-based therapies, through the rational engineering design of mRNA components, combined with novel structural RNAs and novel delivery vehicles.

AB - RNA forms of CRISPR-Cas9-based gene therapies provide more safer and effective therapeutic outcomes. This paper offers a reference for improving the effects of RNA forms of CRISPR-Cas9-based therapies, through the rational engineering design of mRNA components, combined with novel structural RNAs and novel delivery vehicles.

U2 - 10.1016/j.omtn.2025.102737

DO - 10.1016/j.omtn.2025.102737

M3 - Review Article or Literature Review

SN - 2162-2531

VL - 36

JO - Molecular Therapy Nucleic Acids

JF - Molecular Therapy Nucleic Acids

IS - 4

M1 - 102737

ER -

Unlocking mRNA-driven CRISPR-Cas9 gene therapy via optimizing mRNA and the delivery vectors

Sammanfattning

Åtkomst av dokument

Fingeravtryck

Utrustning

Åbo Akademi Functional Printing Center

Projekt

MADNESS: Centre of Excellence in Materials-driven solutions for combatting antimicrobial resistance

PII: Printed Intelligence Infrastructure

Citera det här